71 related articles for article (PubMed ID: 1828173)
1. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Lønning PE; Eikesdal HP
Endocr Relat Cancer; 2013 Aug; 20(4):R183-201. PubMed ID: 23625614
[TBL] [Abstract][Full Text] [Related]
2. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Geisler J
Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
[TBL] [Abstract][Full Text] [Related]
3. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.
Lønning PE
Ann Oncol; 2011 Mar; 22(3):503-514. PubMed ID: 20616198
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Sainsbury R
Br J Cancer; 2004 May; 90(9):1733-9. PubMed ID: 15150604
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha in human breast cancer: occurrence and significance.
Ali S; Coombes RC
J Mammary Gland Biol Neoplasia; 2000 Jul; 5(3):271-81. PubMed ID: 14973389
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of aromatase inhibitors and inactivators.
Lønning P
Clin Pharmacokinet; 2003; 42(7):619-31. PubMed ID: 12844324
[No Abstract] [Full Text] [Related]
7. Aromatase inhibitors and inactivators for breast cancer therapy.
Lønning PE
Drugs Aging; 2002; 19(4):277-98. PubMed ID: 12038879
[TBL] [Abstract][Full Text] [Related]
8. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
[TBL] [Abstract][Full Text] [Related]
10. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Johannessen DC; Adlercreutz H; Fotsis T; Lønning PE
Br J Cancer; 1993 Aug; 68(2):393-8. PubMed ID: 8135918
[TBL] [Abstract][Full Text] [Related]
11. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.
Lønning PE; Lien EA; Lundgren S; Kvinnsland S
Clin Pharmacokinet; 1992 May; 22(5):327-58. PubMed ID: 1505141
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors in malignant diseases of aging.
Johannessen DC; Lønning PE
Drugs Aging; 1992; 2(6):530-45. PubMed ID: 1493356
[TBL] [Abstract][Full Text] [Related]
14. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Lønning PE; Dowsett M; Jones A; Ekse D; Jacobs S; McNeil F; Johannessen DC; Powles TJ
Breast Cancer Res Treat; 1992; 23(1-2):57-62. PubMed ID: 1446052
[TBL] [Abstract][Full Text] [Related]
15. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
[TBL] [Abstract][Full Text] [Related]
16. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
Lønning PE; Jacobs S; Jones A; Haynes B; Powles T; Dowsett M
Br J Cancer; 1991 May; 63(5):789-93. PubMed ID: 1828173
[TBL] [Abstract][Full Text] [Related]
17. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
18. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Dowsett M; Stein RC; Mehta A; Coombes RC
Clin Endocrinol (Oxf); 1990 May; 32(5):623-34. PubMed ID: 2142026
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
